Press Room

Press Release / Feb 21, 2001

Speech delivered by Mr. António Guterres, Prime Minister

on the occasion of his visit to Hovione on 21st February 2001

Speech delivered by Mr. António Guterres, Prime Minister | Hovione

(transcribed and translated at Hovione)

The reason for this visit is very simple:

It was recently decided by both the Government and all social partners, that we would get together to work with well defined objectives, with a view to significatively improving, here in Portugal, both hygiene, safety at work and our fight against accidents, as well as increasing training and qualification of people at work who create prosperity. It is important to say that on signing the agreement relating to hygiene and safety at work, we assumed that, unfortunately, our Country, is lacking in these fields and, in certain sectors, has an accident rate which is intolerable both from a political and moral point of view relative to the people who work and live in Portugal.

It could be thought that these objectives are utopic, but the best way to show that this is not so, is to visit a company that for a long time, and at its own initiative and according to its own strategy, is a centre of excellence. This I take as an example that the Country should know about, not only, but also, in relation to the question of safety. This is the best way to prove to those who do not have this preoccupation sufficiently in mind, what they can and should do and by doing so would not necessarily increase their costs, on the contrary, as has just been mentioned, they could even lower their production costs.

Obviously, safety is not exclusively a worry for firms. The State, as regulator and inspector - must recognize that not having done enough in this field is a worry for the firms – but it is also the responsibility of those who work to behave in a matter that safeguards themselves and others.

We felt that it was very important that the Country should know Hovione because what is done here in this field is absolutely exemplary and can and should, bearing in mind that natural adaptations required according to the different forms of the country’s economic activity, be copied across the Country, showing that the objectives we have set ourselves, on a country wide scale, are perfectly attainable.

Actually, I must refer to another aspect that mentioned here. We have established in our social agreements the right to training. This right, independently from other aspects, assures that all Portuguese workers by 2005 will enjoy 35 hours/year of training. Hovione already offers 70 hours/year training. It is also interesting that training is not something that has been imposed, as a luxury or a political option. In a firm of excellence that assures high standards of technology and is a name in the marketplace, training is an essential component for its own success. At the same time, in this world of constant mutation, it is fundamental to give people the capacity to reply to challenges that are renewed daily as a result of the rapid technological evolution that we live with.

But it would be unjust if I did not take advantage of this occasion to state, in the name of the Government, our great appreciation of what Hovione means to Portugal, and not only in what refers to the questions of safety and training. It is a case of quite exemplary capacity for technological innovation and the proof that when we want to, when we really do everything we can and with enormous determination, the conditions exist in Portugal to do as well as anywhere in the world. However, this is not viable without enormous investment, tremendous dedication, effort and competence.

I know that several decades ago, Eng. Ivan Villax started in a small laboratory in a cellar. From that small laboratory to what we see here today, there are decades of hard work, of competence, of intelligence which, put to work towards an ideal, assured the building of this enterprise. I feel this is an example to be followed as it demonstrates that it is possible, in Portugal, to achieve the best there is in the World and to have things for which we can be proud from every angle. Such as the matters related to technological capacity, innovation, optimization of management, to all those equally important matters of safety and training in social conscience and of belonging to a community. Many firms tend to function isolated from the community without realizing the importance of being part of it.

It is also exemplary that this firm has understood that they can only win by maintaining a constant dialogue with the local community enrichening it at the same time. For all of this, many thanks for this opportunity for the country, more than for myself as I have known of the tradition of excellence that you represent, to grow in self esteem and understand that they too can achieve their own objectives if there is the will and the capacity to do so.

Many thanks.

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025